Methods and compositions for diagnosing, prognosing, and treating neurological conditions
AssigneesPopulation Diagnostics, Inc., The Research Foundation of State University of New York
InventorsELI HATCHWELL, PEGGY S. EIS
Life of this patent
Estimating the term…
Abstract
This document provides methods and materials related to genetic variations of neurological disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Parkinson's disease.
Claims64
A method of screening one or more subjects for at least one genetic variation comprising:
- assaying at least one nucleic acid sample obtained from each of the one or more subjects for the at least one genetic variation that disrupts or modulates one or more genes in Table 3.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-72. (canceled)
A method of screening for a therapeutic agent for treatment of an ND, comprising identifying an agent that disrupts or modulates one or more genes in Table 3, one or more genomic sequences of SEQ ID NOs 383 to 1020, or one or more expression products thereof, wherein the one or more expression products thereof are selected from the group consisting of RNA transcripts and polypeptides.
(canceled)
(canceled)
-84. (canceled)
-90. (canceled)
A kit for screening for an ND in one or more subjects, the kit comprising reagents for assaying a nucleic acid sample from the one or more subjects for the presence of at least one genetic variation encoded by any one of SEQ ID NOs 1-382, or at least one genetic variation that disrupts or modulates a genomic sequence encoded by any one of SEQ ID NOs 383 to 1020 or expression of an RNA transcript or polypeptide expressed therefrom.
-103. (canceled)
An isolated polynucleotide sequence or fragment thereof, comprising at least 60% identity to any one of SEQ ID NOs 1 to 382 or a genetic variation that disrupts or modulates a genomic sequence encoded by any one of SEQ ID NOs 383 to 1020, or a compliment thereof, wherein the isolated polynucleotide sequence, or fragment thereof, is hybridized to a synthetic oligonucleotide.
-114. (canceled)
-119. (canceled)
A cDNA encoded by an RNA sequence transcribed from any one of SEQ ID NOs 383 to 1020.
A host cell comprising an expression control sequence operably linked to a polynucleotide sequence selected from the group consisting of a polynucleotide sequence encoded by any one of SEQ ID NOs 383 to 1020, or a fragment thereof.
-127. (canceled)
A panel of biomarkers for detection of an ND comprising two or more fragments of (a) one or more polynucleotide sequences selected from SEQ ID NOs 1 to 382, or (b) one or more polynucleotide sequences containing a genetic variation that disrupts or modulates a genomic sequence encoded by any one of SEQ ID NOs 383 to 1020.
(canceled)
(canceled)
(canceled)
-139. (canceled)
A method for measuring expression levels of polynucleotide sequences from biomarkers for an ND in a subject, comprising:
- a) selecting a panel of biomarkers comprising two or more genes contained in one or more polynucleotide sequences selected from SEQ ID NOs 383 to 1020;
- b) isolating cellular RNA from a nucleic acid sample obtained from the subject;
- c) synthesizing cDNA from the cellular RNA for each biomarker in the panel using suitable primers;
- d) optionally amplifying the cDNA;
- and
- e) quantifying levels of the cDNA from the nucleic acid sample.
-148. (canceled)
A method for measuring expression levels of polypeptides from biomarkers for an ND in a subject comprising:
- a) selecting a panel of biomarkers comprising at least two polypeptides encoded by an RNA sequence transcribed from a genomic sequence of SEQ ID NOs 383 to 1020;
- b) obtaining a polypeptide sample from the subject;
- c) creating an antibody/aptamer panel for each biomarker in the panel;
- d) using the antibody/aptamer panel to bind the polypeptides from the polypeptide sample;
- and
- e) quantifying levels of the polypeptides bound from the polypeptide sample to the antibody/aptamer panel.
-199. (canceled)
Dependencies are inferred from the claim text.